On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded with the approval of the draft for the 2025 edition of the Chinese Pharmacopoeia (ChP 2025 Edition). The approval paves the way for the imminent implementation of the new edition.
Enhancements in Scientificity and Standardization
The ChP 2025 Edition has seen significant improvements in terms of scientificity, systematicity, safety, and standardization. These enhancements are designed to create a comprehensive drug standard system that encompasses a wide range of pharmaceutical products. According to Li Li, director of the National Medical Products Administration (NMPA), the new edition will cover Chinese medicinal materials, Chinese herbal pieces, traditional Chinese patent medicines and simple preparations, chemicals, biological products, pharmaceutical excipients, drug packaging materials, and more.
Comprehensive Coverage of Pharmaceutical Standards
The ChP 2025 Edition aims to provide a unified and scientifically rigorous framework for the evaluation and regulation of pharmaceuticals in China. The updated edition will play a crucial role in ensuring the quality, safety, and efficacy of medicines, supporting the advancement of the pharmaceutical industry and protecting public health.-Fineline Info & Tech
